Format

Send to

Choose Destination
Annu Rev Pathol. 2016 May 23;11:617-44. doi: 10.1146/annurev-pathol-012414-040349. Epub 2016 Mar 17.

The Roles of MDM2 and MDMX in Cancer.

Author information

1
Department of Biological Sciences, Columbia University, New York, NY 10027; email: clp3@columbia.edu.

Abstract

For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been shown to exert oncogenic activity. These two proteins are best understood as negative regulators of the p53 tumor suppressor, although they may have additional p53-independent roles. Understanding the dysregulation of MDM2 and MDMX in human cancers and how they function either together or separately in tumorigenesis may improve methods of diagnosis and for assessing prognosis. Targeting the proteins themselves, or their regulators, may be a promising therapeutic approach to treating some forms of cancer.

KEYWORDS:

MDM2; MDMX; cancer; p53; tumorigenesis

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center